New trends in the management of mycosis fungoides and Sezary syndrome;Nowe trendy w leczeniu ziarniniaka grzybiastego i zespołu Sezary'ego

Postepy Dermatologii i Alergologii

Volumn 26, Issue 1, 2009, Pages 41-55

  Batycka Baran, Aleksandra ^a   Reich, Adam ^a   Jankowska Konsur, Alina ^a   Maj, Joanna ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Immunomodulators; Mycosis fungoides; Primary cutaneous T cell lymphomas; Sezary syndrome; Skin oriented therapy

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; DENILEUKIN DIFTITOX; FORODESINE; HISTONE DEACETYLASE INHIBITOR; METHOTREXATE; PURINE DERIVATIVE; RETINOID; TOLL LIKE RECEPTOR AGONIST; ZANOLIMUMAB;

CANCER STAGING; COMBINATION CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; HUMAN; IMMUNOMODULATION; LONG TERM CARE; MYCOSIS FUNGOIDES; PATHOGENESIS; PUVA; REVIEW; SEZARY SYNDROME; SYSTEMIC THERAPY; T LYMPHOCYTE;

EID: 70349566053     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Smith BD, Wilson LD. Cutaneous lymphoma. Curr Probl Cancer 2008; 32: 43-87.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785
3. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-1030
4. Huber MA, Staib G, Pehamberger H, Scharffetter-Kochanek K. Management of refractory early-stage cutaneous T-cell lymphoma. Am J Clin Dermatol 2006; 7: 155-169 (Pubitemid 43845340)
5. Pimpinelli N, Olsen EA, Santucci M, et al.; International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053-1063
6. Sokołowska-Wojdyło M, Nedoszytko B, Zabłotna M i wsp. Diagnostyka genetyczna chłoniaków T-komórkowych pierwotnie wywodza̧cych siȩ ze skóry. Czȩś ć I: Zastosowanie analizy rearanżacji genu receptora TCR w diagnostyce chłoniaków pierwotnie skórnych z komórek T. Post Dermatol Alergol 2007; 24: 151-156
7. Vonderheid EC, Bernengo MG, Burg G, et al.; ISCL. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95-106.
8. Jones D, Dang NH, Duvic M, et al. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001; 115: 885-892 (Pubitemid 32476716)
9. Bernengo MG, Novelli M, Quaglino P, et al. The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells. Br J Dermatol 2001; 144: 125-135 (Pubitemid 32154603)
10. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome. Clin Exp Dermatol 2005; 30: 702-706 (Pubitemid 41499832)
11. Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology (Williston Park) 2007; 21 (2 Suppl 1): 33-40.
12. Bunn PA Jr, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 197; 63: 725-728
13. Sokołowska-Wojdyło M, Roszkiewicz J. Pierowotne chłoniaki skóry. Wydawnictwo Czelej, Lublin 2008.
14. Olsen E, Vonderheid E, Pimpinelli N, et al.; ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722
15. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139: 857-866 (Pubitemid 36898920)
16. Stadler R. Optimal combination with PUVA: rationale and clinical trial update. Oncology (Williston Park) 2007; 21 (2 Suppl 1): 29-32.
17. th International Symposium on the biology and Immunology of Cutaneous Lymphomas, Berlin (Germany), January 10-12, 2008, Abstract 38.
18. Hymes KB. Choices in the treatment of cutaneous T-cell lymphoma. Oncology (Williston Park) 2007; 21 (2 Suppl 1): 18-23.
19. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998; 134: 949-954
20. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol 2003; 139: 165-173 (Pubitemid 36216254)
21. Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990; 22: 802-810
22. Gniadecki R, Assaf C, Bagot M, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 57: 433-440 (Pubitemid 47256108)
23. Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 2005; 141: 305-311 (Pubitemid 40365446)
24. Soung J, Muigai W, Amin N, et al. A chart review of patients with early stage mycosis fungoides treated with psoraleny plus UVA (PUVA). J Drugs Dermatol 2005; 4: 290-294
25. Diederen PV, van Weelden H, Sanders CJ, et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 2003; 48: 215-219 (Pubitemid 36232319)
26. Heald P, Mehlmauer M, Martin AG, et al.; Worldwide Bexarotene Study Group. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 2003; 49: 801-815 (Pubitemid 37314867)
27. Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol 2004; 50: 600-607 (Pubitemid 38393171)
28. Demierre MF, Vachon L, Ho V, et al. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides. Arch Dermatol 2003; 139: 624-628 (Pubitemid 36576378)
29. Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol 2005; 52: 275-280
30. Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol 2002; 27: 516-518 (Pubitemid 35278948)
31. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-3581
32. Stadler R, Kremer A, Luger T, et al. Prospective, randomized, multicenter clinical trial on the use of interferon -2a plus PUVA versus PUVA in patients with cutaneous T-cell lymphoma stages I and II. J Clin Oncol 2006; 24 (18 Suppl): 7541.
33. Rupoli S, Goteri G, Pulini S, et al.; Marche Regional Multicentric Study Group of Cutaneous Lymphomas. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 2005; 75: 136-145
34. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol 2004; 51: 570-573 (Pubitemid 39278076)
35. Kreuter A, Altmeyer P. Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sézary syndrome. J Am Acad Dermatol 2005; 53: 1093-1095 (Pubitemid 41677346)
36. Kempf W, Kettelhack N, Duvic M, Burg G. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17: 1405-1419 (Pubitemid 37523677)
37. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-593 (Pubitemid 32458440)
38. Duvic M, Hymes K, Heald P, et al.; Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471 (Pubitemid 32391217)
39. Bouwhuis SA, Davis MD, el-Azhary RA, et al. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients. J Am Acad Dermatol 2005; 52: 991-996
40. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 311-321 (Pubitemid 38044675)
41. Vegna ML, Papa G, Defazio D, et al. Interferon alpha-2a in cutaneous T-cell lymphoma. Eur J Haematol Suppl 1990; 52: 32-35 (Pubitemid 20375387)
42. Jumbou O, N'Guyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa. Br J Dermatol 1999; 140: 427-431 (Pubitemid 29182872)
43. Marolleau JP, Baccard M, Flageul B, et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995; 131: 574-579
44. Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003; 17: 1435-1448 (Pubitemid 37523679)
45. Duvic M, Sherman ML, Wood GS, et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 2006; 55: 807-813 (Pubitemid 44556848)
46. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-388
47. Foss F. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006; 33 (1 Suppl 3): S11-6. (Pubitemid 43306775)
48. Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005; 106: 454-457 (Pubitemid 40981237)
49. Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007; 109: 1799-1803 (Pubitemid 46668543)
50. McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004; 50: 375-379 (Pubitemid 38316130)
51. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18: 2603-2606 (Pubitemid 30432527)
52. Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006; 7: 51-58 (Pubitemid 44322770)
53. Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104: 2437-2441 (Pubitemid 41691565)
54. Mazur G, Maj J, Wrobel T, et al. Treatment of cutaneous T-cell lymphomas with purine analogues (fludarabine and 2-chlorodeoxyadenosine). J BUON 2003; 8: 247-251
55. Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000; 42: 40-46
56. Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003; 98: 993-1001. (Pubitemid 37022100)
57. Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999; 86: 1368-1376 (Pubitemid 29447025)
58. Scarisbrick JJ, Child FJ, Clift A, et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 2001; 144: 1010-1015
59. Zackheim HS, Epstein EH Jr. Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 1989; 21: 757-762
60. Allen C, Saigal K, Nottingham L, et al. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-kappaB subunits in head and neck cancer. Clin Cancer Res 2008; 14: 4175-4185
61. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267-4272
62. Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 2003; 71: 250-256 (Pubitemid 37174695)
63. Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92: 784-794 (Pubitemid 350155304)
64. th International Symposium on the biology and Immunology of Cutaneous Lymphomas, Berlin (Germany), January 10-12, 2008, Abstract 52.
65. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655-4662 (Pubitemid 46827755)
66. Marks PA, Richon VM, Miller T, et al. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-168
67. Zhang C, Richon V, Ni X, et al. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005; 125: 1045-1052
68. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2008; 26: 332-333
69. Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008; 68: 3785-3794
70. th International Symposium on the biology and Immunology of Cutaneous Lymphomas, Berlin (Germany), January 10-12, 2008, Abstract 11.
71. Piekarz R, Frye R, Turner M, et al. Update on the Phase II trial and correlative studies of patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. J Clin Oncol 2004; 14 Suppl: 3028.
72. Piekarz RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004; 103: 4636-4643 (Pubitemid 38745996)
73. Dummer R. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL). Semin Oncol 2006; 33 (1 Suppl 3): S33-6.
74. Dummer R, Hassel JC, Fellenberg F, et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004; 104: 1631-1638 (Pubitemid 39202268)
75. th International Symposium on the biology and Immunology of Cutaneous Lymphomas, Berlin (Germany), January 10-12, 2008, Abstract 41.
76. Girardi M, Knobler R, Edelson R. Selective immunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow. Hematol Oncol Clin North Am 2003; 17: 1391-1403 (Pubitemid 37523676)
77. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002; 138: 1054-1060
78. Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003; 16: 337-346 (Pubitemid 38044678)
79. Evans AV, Wood BP, Scarisbrick JJ, et al. Extracorporeal photopheresis in Sézary syndrome: hematologic parameters as predictors of response. Blood 2001; 98: 1298-1301
80. Knobler R, Jantschitsch C. Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apher Sci 2003; 28: 81-89 (Pubitemid 36298594)
81. McGinnis KS, Shapiro M, Vittorio CC, et al. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003; 139: 771-775 (Pubitemid 36705945)
82. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1057-1076
83. Dearden C. Is there a role for hemopoetic stem-cell transplantation in CTCL? Oncology (Williston Park) 2007; 21 (2 Suppl 1): 24-28
84. Dummer R, Assaf C, Bagot M, et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer 2007; 43: 2321-2329 (Pubitemid 350001246)